Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03911973
Title Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Kari Wisinski
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Gedatolisib + Talazoparib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Northwestern University Feinberg School of Medicine Recruiting Chicago Illinois 60611 United States Details
University of Illinois Cancer Center Recruiting Chicago Illinois 60612 United States Details
Indiana University Melvin and Bren Simon Comprehensive Cancer Center Recruiting Indianapolis Indiana 46202 United States Details
University of Iowa Hospital and Clinics Recruiting Iowa City Iowa 52242 United States Details
University of Wisconsin Recruiting Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field